US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
USOTC
NGE Capital Ltd (PK) (NGELF) 銘柄情報

NGE Capital Ltd (PK) (NGELF)

0.6288

0.00

(0.00%)

終了 6月16日 5:00AM

NGE Capital Ltd (PK) (NGELF) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.6288

( - )

買値

0.0001

売値

500.91

出来高

-

0.00 日の範囲 0.00

0.6288 52 週間の範囲 0.6288

時価総額

前日終値

0.6288

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 51,083

発行済株式数

33,631,211

配当利回り

PER

3.59

1 株当たり利益 (EPS)

0.35

歳入

933k

純利益

12.02M

NGE Capital Limited operates as an investment company in Australia. It invests in listed and unlisted securities. The company was formerly known as New Guinea Energy Limited and changed its name to NGE Capital Limited in June 2017. NGE Capital Limited was founded in 2005 and is based in Melbourne, A... NGE Capital Limited operates as an investment company in Australia. It invests in listed and unlisted securities. The company was formerly known as New Guinea Energy Limited and changed its name to NGE Capital Limited in June 2017. NGE Capital Limited was founded in 2005 and is based in Melbourne, Australia. 詳細を表示

セクター

Finance

業界

Asset Management Services

ウェブサイト

www.ngecapital.com.au

本社

South Melbourne, Australia

設立

2026

NGE Capital Ltd (PK) is listed in the Finance sector of the その他OTC with ticker NGELF. The last closing price for NGE Capital (PK) was US$0.63. Over the last year, NGE Capital (PK) shares have traded in a share price range of US$ 0.6288 to US$ 0.6288.

NGE Capital (PK) currently has 33,631,211 shares in issue. The market capitalisation of NGE Capital (PK) is US$21.15 million. NGE Capital (PK) has a price to earnings ratio (PE ratio) of 3.59.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0.6288	0.6288	0.6288	0	0	CS
26	0	0	0.6288	0.6288	0.6288	0	0	CS
52	0	0	0.6288	0.6288	0.6288	0	0	CS
156	0.0538	9.35652173913	0.575	0.73	0.575	156	0.63913677	CS
260	0.1587	33.7587747288	0.4701	0.73	0.46	877	0.50555387	CS

NGELF - Frequently Asked Questions (FAQ)

What is the current NGE Capital Ltd (PK) share price?

The current share price of NGE Capital Ltd (PK) is US$ 0.6288

How many NGE Capital Ltd (PK) shares are in issue?

NGE Capital Ltd (PK) has 33,631,211 shares in issue

What is the market cap of NGE Capital Ltd (PK)?

The market capitalisation of NGE Capital Ltd (PK) is USD 21.15M

What is the 1 year trading range for NGE Capital Ltd (PK) share price?

NGE Capital Ltd (PK) has traded in the range of US$ 0.6288 to US$ 0.6288 during the past year

What is the PE ratio of NGE Capital Ltd (PK)?

The price to earnings ratio of NGE Capital Ltd (PK) is 3.59

What is the cash to sales ratio of NGE Capital Ltd (PK)?

The cash to sales ratio of NGE Capital Ltd (PK) is 45.06

What is the registered address of NGE Capital Ltd (PK)?

The registered address for NGE Capital Ltd (PK) is Level 4, South Melbourne, Victoria, 3205

What is the NGE Capital Ltd (PK) website address?

The website address for NGE Capital Ltd (PK) is www.ngecapital.com.au

Which industry sector does NGE Capital Ltd (PK) operate in?

NGE Capital Ltd (PK) operates in the Asset Management Services sector

HyGro

Sorry, not enough. NWBO won't make any profit selling in the UK. NICE hates personalized oncology treatments and won't pay enough for NWBO to make a profit.
That's what counts. And NWBO will go under or just become Advent Contract Manufacturer. They have no cash or credit to fund any sub

biotechinvestor1

biotechinvestor1 6分前

Don’t start spazzing again, Alteogen circus clown. The Sanofi news is old.
Once Merck settles/licenses from Halozyme, Sanofi and all others will follow.
Your Alteogen stole IP from Halozyme and will pay a price for it. You can count on it.
The companies who have signed with Alte

Steady_T

Steady_T 7分前

Your theory will be put to the test after UK approval. I give it 6 months as a guess.

HyGro

What's true is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How many years are you going to wait to find out???

HyGro

What's True is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How long are you going to wait to find out???

Mdk1

Google Scholar alert - new article: "A Comparison of Plasmonic Modulator Structures in the O- and C-Band for the 400G/Lane IM/DD Era"
>>> " In ALL cases, the same electro-optic organic material, Lightwave Logic’s PerkinamineTM
chromophore series 3, was used " !
https://ieeexplor

CelestialSage6

CelestialSage6 14分前

Stop talking nonsense. Sanofi is conducting clinical trials using Alteogen's technology; what are your thoughts on this? Did you sense a crisis for Halozyme?

biotechinvestor1

biotechinvestor1 17分前

I love it when Alteogen fanboys post on this board. Nearly every time they show up, Halozyme has a run up.

DR_rugby

DR_rugby 18分前

Prophecy is coming

https://www.cnbc.com/2026/06/16/boj-rate-hike-historic-inflation.html

Japanese rates are going higher

Yen is yet to be stabilize

The great unwinding is coming soon

GLTA

BigBadWolf

BigBadWolf 24分前

Authorized Shares 1,800,000,000 06/15/2026
Outstanding Shares 1,619,034,363 06/15/2026 >5m
Restricted 480,530,670 06/15/2026 >5m
Unrestricted 1,138,503,693 06/15/2026
Held at DTC 1,011,499,104 06/15/2026 >8m

Authorized Shares 1,800,000,000 06/05/2026

4retire

4retire 28分前

One has to question why a “cash rich” company would need to raise $20-25 billion by going to bond sales that will be in 7 tranches, ranging from 2 to 30 years. The statement is that it’s for general purposes and to redo some current debt financing.

Based on recent financials, NVDA’

tank777

tank777 28分前

FACT CHECK:

The key distinction is between “eligible” and “selected.”

To date, CMS has not publicly released a list of approved CBD brands for the Substance Access Beneficiary Engagement Incentive (BEI) program.

That means:

Mr. Tate

Mr. Tate 28分前

Your Mother should've named you loser0. Awww did someone take your lunch money in school loser0? IMO

jhdf51

jhdf51 28分前

Great.. thank you.

ducci1

ducci1 29分前

Pivot Calcs: SPX Pivot 7549---R1 7582---S1 7521---SPY Pivot 754---R1 757---S1 752----ES Pivot 7601---R1 7667---S1 7555----VIX Pivot 16.35---R1 16.70---S1 15.85---15 min Bull/Bear R/Line 18.34!----!!LOL!!

Mr. Tate

Mr. Tate 30分前

Are you for real loser0? You always hide behind a computer screen loser0? IMO

Wolf-man jack

Wolf-man jack 35分前

WQLF SAYS: .Charlottes Web products Have Not been PUBLICLY STATED as being OFFICIALLY APPROVED. In the case of CV SCIENCES, the CMS Pilot Program still has time to Announce CV SCIENCES or are they already enrolled? Cornbread was never announced, so one can not reliably state that it is A True FACT Y

knrorrel

knrorrel 47分前

Wow, that would be fantastic. It would be a dream come true for me after the many losses (FORW, BLEG, PAVS) this year... I have to admit, the latest news was fantastic; the company shouldn't be trading at this level and could soon see a massive surge—similar to how QBTS went from $0.50 to $20 years

knrorrel

knrorrel 50分前

$GPUS GPUS should make a magnificent, big, and sustained climb now; we just need a little patience, the ability to weather the fluctuations (ups and downs), and steady nerves. Ultimately, however, we should be trading in the multi-dollar range., all only imho

many great news &

nwtf

And why would we own this pos? You act like us knowing this is not a good investment is a bad thing?

knrorrel

knrorrel 51分前

$GPUS GPUS should make a magnificent, big, and sustained climb now; we just need a little patience, the ability to weather the fluctuations (ups and downs), and steady nerves. Ultimately, however, we should be trading in the multi-dollar range., all only imho

knrorrel

knrorrel 54分前

$GPUS many great news 🔥 strong undervalued https://www.otcmarkets.com/stock/GPUS/news

OTC Market Seite

https://www.otcmarkets.com/stock/GPUS/profile

knrorrel

knrorrel 54分前

many great news 🔥 strong undervalued https://www.otcmarkets.com/stock/GPUS/news

OTC Market Seite

https://www.otcmarkets.com/stock/GPUS/profile

nwtf

nwtf 1時間前

You are wrong here just as you were on the ERHE board spewing the same unproven narrative.

NGE Capital (PK)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。